Yang Meijia, Wei Heng, Wang Yuelong, Deng Jiaojiao, Tang Yani, Zhou Liangxue, Guo Gang, Tong Aiping
The State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
College of Life Science, Sichuan University, Chengdu 610064, China.
Mol Ther Nucleic Acids. 2017 Sep 15;8:450-458. doi: 10.1016/j.omtn.2017.05.009. Epub 2017 May 17.
BRAF-V600E (1799T > A) is one of the most frequently reported driver mutations in multiple types of cancers, and patients with such mutations could benefit from selectively inactivating the mutant allele. Near this mutation site, there are two TTTN and one NGG protospacer-adjacent motifs (PAMs) for Cpf1 and Cas9 CRISPR nucleases, respectively. The 1799T > A substitution also leads to the occurrence of a novel NGNG PAM for the EQR variant of Cas9. We examined the editing efficacy and selectivity of Cpf1, Cas9, and EQR variant to this mutation site. Only Cpf1 demonstrated robust activity to induce specific disruption of only mutant BRAF, not wild-type sequence. Cas9 recognized and cut both normal and mutant alleles, and no obvious gene editing events were observed using EQR variant. Our results support the potential applicability of Cpf1 in precision medicine through highly specific inactivation of many other gain-of-function mutations.
BRAF-V600E(1799T>A)是多种癌症中报道最为频繁的驱动突变之一,具有此类突变的患者可通过选择性使突变等位基因失活而获益。在该突变位点附近,分别存在两个TTTN和一个NGG原间隔相邻基序(PAM),用于Cpf1和Cas9 CRISPR核酸酶。1799T>A替换还导致出现了一种针对Cas9的EQR变体的新型NGNG PAM。我们检测了Cpf1、Cas9和EQR变体对该突变位点的编辑效率和选择性。只有Cpf1表现出强大的活性,能特异性地仅破坏突变型BRAF,而不影响野生型序列。Cas9识别并切割正常和突变等位基因,使用EQR变体未观察到明显的基因编辑事件。我们的结果支持了Cpf1通过高度特异性地使许多其他功能获得性突变失活而在精准医学中的潜在适用性。